Relevant bibliographies by topics / Osteoporsis / Journal articles
To see the other types of publications on this topic, follow the link: Osteoporsis.

Journal articles on the topic 'Osteoporsis'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Osteoporsis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Byun, Young Soon, and Ok Soo Kim. "Life Style and Self-efficacy in Osteoporsis Women." Journal of Korean Academy of Nursing 29, no. 3 (1999): 530. http://dx.doi.org/10.4040/jkan.1999.29.3.530.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kruger, Marlena C., and David F. Horrobin. "Calcium metabolism, osteoporsis and essential fatty acids: A review." Progress in Lipid Research 36, no. 2-3 (September 1997): 131–51. http://dx.doi.org/10.1016/s0163-7827(97)00007-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Narita, Syugo, Masanori Nakashima, and Yasushi Yamashita. "Bone mineral density by digital image processing method in patients with osteoporsis." Orthopedics & Traumatology 39, no. 2 (1990): 430–32. http://dx.doi.org/10.5035/nishiseisai.39.430.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

ul Haq, N., M. Tahir, Q. Iqbal, A. Naseem, S. Mohammd, N. Ahmed, and S. A. Azhar. "Assessment of Osteoporsis Knowledge And Perception Among Female University Students In Quetta, Pakistan." Value in Health 18, no. 3 (May 2015): A169. http://dx.doi.org/10.1016/j.jval.2015.03.976.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pinho, Mara Suzana. "Osteoporos e Osteoporosis." Revista Brasileira de Reumatologia 43, no. 3 (June 2003): 185–88. http://dx.doi.org/10.1590/s0482-50042003000300011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sánchez Márquez, Pedro, and Carlos Arturo Révérend Lizcano. "Factores de diferenciación génica y su futuro en el tratamiento de la osteoporosis: de la adipogénesis a la osteoblastogénesis, ¿del mismo modo y en sentido contrario?" Revista Colombiana de Endocrinología, Diabetes & Metabolismo 5, no. 4 (November 20, 2018): 21–25. http://dx.doi.org/10.53853/encr.5.4.450.

Full text
Abstract:
El presente artículo tiene como objetivo presentar de forma resumida los diferentes factores que están involucrados en la diferenciación y el mantenimiento del fenotipo óseo, en contraste con los factores adipogénicos, cuya expresión determina procesos de diferenciación mutuamente excluyentes. Por otro lado, se propone el posible uso terapéutico para distintas patologías óseas como la osteoporosis. Los datos fueron obtenidos de estudios clínicos aleatorizados y de revisión, en idioma español e inglés, de los últimos 15 años, que incluyeran los términos Mesh: Osteoporosis; Osteoporoses; Osteoporosis, Post-Traumatic; Osteoporosis, Senile; Osteoporosis, Age-Related; Bone Loss, Age-Related; Factors, Transcription; Transcription Factor; Adipogeneses; Bone Formation; Osteoclastogenesis; Endochondral Ossification; Endochondral Ossifications; Ossification, Endochondral; Ossification, Physiological; Ossification, Physiologic.
APA, Harvard, Vancouver, ISO, and other styles
7

Baccichetti, A., P. L. Nguyen-Thi, A. Blum, D. Mainard, F. Sirveaux, L. Nace, A. Valance, et al. "SAT0459 EVALUATION OF THE PREVALENCE AND THE MANAGEMENT OF OSTEOPOROTIC FRACTURES IN PATIENTS HOSPITALIZED AT NANCY UNIVERSITY HOSPITAL (FRANCE) IN 2017." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1187.1–1187. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3366.

Full text
Abstract:
Background:Osteoporotic fractures are a major public health concern because of their consequences in morbidity, costs and mortality. In the meantime, historically postfracture osteoporosis medication use rates have been poor.Objectives:The aim is to analyze the management of osteoporosis in patients hospitalized for osteoporotic fractures (OF) at Nancy University Hospital (France) in 2017.Methods:Total number of hospitalized patients and hospital stays were extracted by the Department of Medical Information (DIM) which selected departments with at least forty hospitalizations with Medical Unit Summary related to a diagnosis of fracture or osteoporosis. Hospitalizations not concerned by a recent OF were excluded. Data on fractures, patient characteristics, risk factors for OF and fall, management of osteoporosis, discharge status, stay duration, were studied from patient medical records. Prevalence of OF stays, management of osteoporosis and factors associated with duration of stay were analyzed.Results:Out of a total of 153,840 hospitalizations, 918 hospitalizations (844 patients, mean age 74.5 years ± 13.6, 74.5% women) concern an OF. The prevalence of hospitalizations for OF was 0.6% of total hospitalizations and 17.9% of total hospitalizations for fractures. Among the 844 patients, 85.7% had a severe fracture (vertebral fracture: 56.2%, hip fracture: 24.1%), 16.5% had a non-severe fracture, and 8.5% had a fracture cascade in the year. At discharge from hospital, 11.7% of patients received a specific treatment for osteoporosis. Longer stay duration was associated with age, severe fractures, Groll index and discharge status.Conclusion:Nearly one hospitalized fracture in five is osteoporotic, while only one in ten patients is treated for osteoporosis. Stay duration increased with age and comorbidities. This encourages the development of early prevention, screening and treatment strategies for osteoporosis.References:[1]Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136.[2]Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006 Oct 19;17(12):1726–33.[3]Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD. Fragility Fractures and the Osteoporosis Care Gap: An International Phenomenon. Semin Arthritis Rheum. 2006 Apr;35(5):293–305.Disclosure of Interests:None declared
APA, Harvard, Vancouver, ISO, and other styles
8

ASLAN, Gulpinar, and Dilek KILIC. "OSTEOPOROSIS HEALTH BELIEF, KNOWLEDGE LEVEL AND RISK FACTORS IN INDIVIDUALS WHOSE BONE MINERAL DENSITY WAS REQUIRED." Belitung Nursing Journal 3, no. 3 (June 7, 2017): 162–73. http://dx.doi.org/10.33546/bnj.67.

Full text
Abstract:
Aim: This descriptive-relational study aims to identify osteoporosıs health belief, knowledge level and risk factors in individuals whose bone mineral density was required.Method: Target population of the study was 110 men and 126 women aged 35 and over, who applied to Atatürk University Aziziye - Yakutiye Research Hospital Nuclear Medicine Center Bone Densitometer Unit between January 2010 and October 2010. No sampling was performed, the whole target population was involved in the study. Data were collected through the Personal Information Form that included socio-demographic features, The Osteoporosis Health Belief Scale, the Osteoporosis Self-Efficacy Scale and the Osteoporosis Knowledge Test.Results: The Osteoporosis Health Belief score of the participants was 139.99±14.79, Osteoporosis Knowledge score was 10.06±4.30, and Osteoporosis Self-Efficacy score was 742.00±213.44. Among Osteoporosis health beliefs, women’s Susceptibility, Seriousness, Barriers of Exercise, and Barriers of Calcium mean scores were found to be higher than those of men (p<0.001). Men’s Osteoporosis Self-Efficacy scale and sub-dimensions mean scores were found to be higher in comparison to women (p<0.001). DEXA analysis results show that 57.1% of the women and 27.3% of the men were diagnosed with osteoporosis. Conclusion: According to the Logistic regression analysis that aimed to identify the risk factors having roles in Osteoporosis diagnosis, the affecting risk factors were gender, age, and medicine use. As for women, logistic regression analysis showed that the risk factors were education level – being illiterate, medicine use, osteoporosis story in family, and 4 or more deliveries.
APA, Harvard, Vancouver, ISO, and other styles
9

De Martinis, Massimo, Lia Ginaldi, Maria Maddalena Sirufo, Giovanni Pioggia, Gioacchino Calapai, Sebastiano Gangemi, and Carmen Mannucci. "Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review." Medicina 56, no. 3 (March 19, 2020): 138. http://dx.doi.org/10.3390/medicina56030138.

Full text
Abstract:
Alarmins are endogenous mediators released by cells following insults or cell death to alert the host’s innate immune system of a situation of danger or harm. Many of these, such as high-mobility group box-1 and 2 (HMGB1, HMGB2) and S100 (calgranulin proteins), act through RAGE (receptor for advanced glycation end products), whereas the IL-1 and IL-33 cytokines bind the IL-1 receptors type I and II, and the cellular receptor ST2, respectively. The alarmin family and their signal pathways share many similarities of cellular and tissue localization, functions, and involvement in various physiological processes and inflammatory diseases including osteoporosis. The aim of the review was to evaluate the role of alarmins in osteoporosis. A bibliographic search of the published scientific literature regarding the role of alarmins in osteoporosis was organized independently by two researchers in the following scientific databases: Pubmed, Scopus, and Web of Science. The keywords used were combined as follows: “alarmins and osteoporosis”, “RAGE and osteoporosis”, “HMGB1 and osteoporosis”, “IL-1 and osteoporosis”, “IL 33 and osteopororsis”, “S100s protein and osteoporosis”. The information was summarized and organized in the present review. We highlight the emerging roles of alarmins in various bone remodeling processes involved in the onset and development of osteoporosis, as well as their potential role as biomarkers of osteoporosis severity and progression. Findings of the research suggest a potential use of alarmins as pharmacological targets in future therapeutic strategies aimed at preventing bone loss and fragility fractures induced by aging and inflammatory diseases.
APA, Harvard, Vancouver, ISO, and other styles
10

Suarni, Leny. "FAKTOR-FAKTOR PENYEBAB TERJADINYA PENYAKIT OSTEOPOROSIS PADA LANSIA DI UPT PELAYANAN SOSIAL LANJUT USIA DI WILAYAH BINJAI TAHUN 2017." Jurnal Riset Hesti Medan Akper Kesdam I/BB Medan 2, no. 1 (June 1, 2017): 60. http://dx.doi.org/10.34008/jurhesti.v2i1.61.

Full text
Abstract:
Osteoporosis is a disease that attacks the bone where the bone becomes brittle (flagella) and is easily broken and fractured. Many of the factors that cause Osteopororsis are one of them is calcium deficiency, especially in childhood to adolescence. By looking at the conditions above, the writer wants to do a research that aims to find out the Factors Causing Osteoporosis in the Elderly in the 2017 Binjai Elderly Service Unit. This research is descriptive with a cross sectional design carried out for the elderly with 25 people. This data collection is done by questionnaire. The results of this study indicate that the factors that cause osteoporosis are calcium deficiency factors as many as 18 people (72%), drug factors as many as 20 people (80%), smoking factors and consuming alcohol as many as 10 people (40%), factors lack of exercise as many as 19 people (76%), and disease factors as many as 15 people (60%). So, it can be concluded that the most dominant cause of osteoporosis in the elderly in the UPT for Elderly Social Services in the Binjai Region in 2017 is 80% Medicines. Therefore, it is expected that the elderly will consume less drugs that can cause Osteoporosis.Keywords: Osteoporosis, Causes of Osteoporosis, Elderly
APA, Harvard, Vancouver, ISO, and other styles
11

Fathala, Ahmed L., Sami Alkulaybi, Abdulrahman Khawaji, Abdelghafour Alomari, and Ahmed Almuhaideb. "The association between low bone mineral density and coronary artery calcification in osteoporotic and non-osteoporotic patients in a tertiary center in Saudi Arabia." Annals of Saudi Medicine 41, no. 2 (April 2021): 101–8. http://dx.doi.org/10.5144/0256-4947.2021.101.

Full text
Abstract:
BACKGROUND: Cardiovascular disease (CVD) and osteoporosis are major health-care concerns worldwide. The evidence is contradictory on whether a relationship exists between low bone mineral density (BMD) determined by dual-energy absorptiometry (DXA scan) and coronary artery calcification (CAC) measured by computed tomography. Currently, there are no data on patients from Saudi Arabia. OBJECTIVE: Examine the relationship between CAC and BMD in both genders and study the influence of traditional coronary artery disease (CAD) risk factors and osteoporosis. DESIGN: Retrospective, cross-sectional, analytical. SETTING: Single tertiary care center. PATIENTS AND METHODS: We searched radiology databases for patients who underwent both DXA and CAC score scanning within six months of each other. The inclusion criterion was an absence of any history of CAD. MAIN OUTCOME MEASURE: Association between osteoporosis and CAC. SAMPLE SIZE: 195 (34 osteoporosic, 161 normal BMD or osteopenic) RESULTS: Most of the study population (57.4%) were females. The mean age of all patients was 63.6 (10.1) years. Participants with CAC scores of 0 were significantly younger than those who had CAC scores >0. The presence of diabetes mellitus, hypertension, and hypercholesterolemia was higher in patients with CAC scores >0. CAC score and other CAD risk factors were not significantly different between the osteoporotic and nonosteoporotic groups, except for body mass index. A high CAC score (>100) was present in 28%, 20%, 11%, and 30% of participants with no osteoporosis, osteoporosis of the lumbar spine, osteoporosis of the femoral neck, and participants with osteoporosis of both the lumbar spine and femoral neck, respectively ( P =.762), suggesting there is no association between CAC and the presence of osteoporosis. CONCLUSIONS: Osteoporosis is not associated with higher CAC scores in Saudi Arabia and CAD risk factors are not significantly prevalent in osteoporosis. It appears that CAC and osteoporosis are independent age-related diseases that share common risk factors. LIMITATIONS: Single-center, retrospective. CONFLICT OF INTEREST: None.
APA, Harvard, Vancouver, ISO, and other styles
12

Anno, S., T. Iida, Y. Yamada, T. Okano, Y. Sugioka, K. Inui, S. Wakitani, and H. Nakamura. "POS1146 ROMOSOZUMAB INCREASE BONE MINERAL DENSITY AT LUMBAR AND FEMORAL IRRESPECTIVE OF PREOSTEOPOROSIS TREATMENT, HISTORY OF FRAGILITY FRACTURE AND COMBINATION OF VITAMIN D." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 901.2–901. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1725.

Full text
Abstract:
BackgroundRomosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. Romosozumab has an excellent therapeutic effect on patients with osteoporosis. However, there are few reports investigated the efficacy and the effect of various factors relative to osteoporosis in real-world.ObjectivesWe evaluated bone mineral density (BMD) and bone metabolism marker (BMM) change in osteoporosis patients treated with romosozumab, and assessed the effect of various factors, such as preosteoporosis treatment, history of fragility fracture and combination of vitamin D.MethodsThis study included 141 osteoporosis patients (132 female, mean age: 78.8 ± 7.5 years, mean hight: 151.1 ± 7.5 cm, mean weight: 50.9 ± 8.9 kg) treated with romosozumab. BMD measurements using dual energy X-ray absorptiometry (DXA) and BMM measurements using N-terminal propeptide of type 1 collagen (P1NP) were evaluated at 0, 4, 6, and 12 months after treatment. DXA were performed at the lumbar spine (n=92), at proximal femoral and femoral neck (n=92), and at distal third radius (n=49). We evaluated the influence of preosteoporosis treatment, history of fragility fracture and combination of vitamin D for BMD change.ResultsBMD at lumbar spine (5.2%: p<0.01, 9.2%: p<0.01, 10.8%: p<0.01), proximal femoral (1.3%: p=0.02, 2.8%: p<0.01, 4.5%: p<0.01) and femoral neck (2.0%: p=0.03, 2.7%: p=0.06, 5.0%: p=0.01) were significantly increased at 4, 8, 12 months after treatment. BMD at distal third radius (-1.5%: p<0.01, -0.8%: p=0.17, -1.0%: p=0.13) were not increased at 4, 8, 12 months after treatment. P1NP chane were 63% (p<0.01), 6.4% (p=0.55), -2.3% (p=0.2) at 4, 8, 12 months after treatment. There were no significant differences in 1 year improvement ratio of BMD at lumbar spine, proximal femoral and femoral neck between 38 patients with pretreatment of osteoporosis and 54 patients without pretreatment of osteoporpsis (13.5 vs 9.5%: p=0.1, 4.9 vs 4.4%: p=0.7, 6.1 vs 4.6%: p=0.67), between 33 patients with a history of fragility fracture and 59 patients without a history of fragility fracture (7.3 vs 11.7%: p=0.42, 0.8 vs 5.5%: p=0.08, -0.7 vs 6.6%: p=0.14), between 50 patients with romosozumab alone and 42 patients with romosozumab plus vitamin D (11.3 vs 10.0%: p=0.93, 4.1 vs 5.3%: p=0.59, 6.8 vs 2.3%: p=0.47). There were no significant differences in 1 year improvement ratio of BMD at distal third radius between 33 patients with pretreatment of osteoporosis and 16 patients without pretreatment of osteoporpsis (-1.1 vs -0.9%: p=0.63), between 31 patients with a history of fragility fracture and 18 patients without a history of fragility fracture (-1.5 vs -0.5%: p=0.3).ConclusionRomosozumab improved BMD at lumbar and femoral independently regardless of preosteoporosis treatment, history of fragility fracture and combination of vitamin D.References[1]Felicia Cosman et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016; 375:1532-1543, DOI: 10.1056/NEJMoa1607948Disclosure of InterestsNone declared
APA, Harvard, Vancouver, ISO, and other styles
13

Tang, Jie, Ping Diao, Xiaohong Shu, Li Li, and Lidan Xiong. "Quercetin and Quercitrin Attenuates the Inflammatory Response and Oxidative Stress in LPS-Induced RAW264.7 Cells: In Vitro Assessment and a Theoretical Model." BioMed Research International 2019 (October 28, 2019): 1–8. http://dx.doi.org/10.1155/2019/7039802.

Full text
Abstract:
Background. Nowadays, atmospheric pollutants, ultraviolet rays, and other factors cause the imbalance of cell redox, resulting in skin oxidative damage. There is an interaction between inflammatory response and oxidative stress, which often involve networks of reactions and serve to amplify each other. Quercetin and quercitrin, with strong antioxidant and anti-inflammatory properties, were widely applied in cardiovascular disease, osteoporsis, pulmonary disease, etc. However, the regulation mechanism of quercetin and quercitrin on various inflammatory skin diseases is still not clear. Purpose. In this study, quercetin and quercitrin were used to investigate whether they had anti-inflammatory and anti-ROS effects. Besides, theoretical calculation method was also adopted to preliminarily explore the mechanism of the anti-inflammatory and antioxidant effects of these two substances. Methods. CCK-8 assay was employed to investigate the cytotoxicity. The concentration of NO measured by Griess Reaction System. Moreover, the inflammatory factors (TNF-α, IL-1β, and IL-6) were reduced in LPS-stimulated RAW264.7 cells were tested by ELISA kits. The trend of ROS changes was detected by DCFH-DA method. Finally, the mechanism of the anti-inflammatory and antioxidant effects of these two substances was carried out by DMol3 package in Materials Studio. Results. CCK-8 assay results guided that the safe concentration of quercetin and quercitrin was lower than 15.0 μg/mL and 22.4 μg/mL, respectively. Also, the concentration of NO could significantly be inhibited by quercetin and quercitrin. Besides, the ELISA results showed that TNF-α, IL-1β, and IL-6 were reduced in LPS-stimulated RAW264.7 cells after interfering with quercetin and quercitrin. The trend of ROS changes was similar to that of inflammatory factors. Finally, the theoretical calculation illustrated that the oxygen atom on B rings may be the main site of electron cloud density changes, which may suggest a possible mechanism for the anti-inflammatory and ROS scavenging effects of quercetin and quercitrin. Conclusions. This experiment shows that LPS can induce the overactivating of macrophages and the activated macrophages can subsequently induce inflammatory storms and oxidative stress. Both quercetin and quercitrin can inhibit LPS-induced macrophage inflammation and oxidative stress by experiment and theoretical calculations.
APA, Harvard, Vancouver, ISO, and other styles
14

Holzer, Gerold, and Lukas A. Holzer. "OSTEOPOROSIS AND JOINT REPLACEMENT." Journal of the Grodno State Medical University 16, no. 3 (2018): 251–56. http://dx.doi.org/10.25298/2221-8785-2018-16-3-251-256.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Nagy, Margit, Csaba Hadházy†, and László Vigváry†. "General symptoms of cornea Salzmann-type degeneration." Orvosi Hetilap 148, no. 9 (March 1, 2007): 413–19. http://dx.doi.org/10.1556/oh.2007.27878.

Full text
Abstract:
A szerzők ismertetik a Salzmann-féle nodularis degeneratio corneae tüneteit, majd beszámolnak 28 betegükről. Minden vizsgált betegnél arthrosis deformanst találtak röntgenvizsgálattal, és csaknem mindegyiküknél osteoporosist. Három beteg bordaporcában szövettani vizsgálattal azonos, foltos jellegű, regresszív elváltozást találtak. 22 betegnél szürkehályog, 20-nál hallászavar is jelentkezett. A betegség ezek alapján a keratochondrosisok közé tartozik. A szerzők táblázatban közlik a Salzmann-betegség és a hozzá hasonló degeneratio corneae nivalis elkülönítését. Következtetések: 1. A corneastroma, a hyalinporcok és csontok elváltozása feltehetően közös komponensüknek a mucopolysaccharidáknak (MPS) a rendellenességén alapszik. 2. Ismeretes, hogy mucopolysaccharida (heparin) huzamos adásával osteoporosist lehet kiváltani. Ez alátámasztja a MPS-ek anyagcserezavara és az osteoporosis közti kapcsolatot. 3. A hasonló korú átlagnépességhez képest feltűnően gyakori szürkehályog és hallászavar szintén a MPS-ek anyagcserezavarán alapulhat. 4. A fentiek amellett szólnak, hogy a Salzmann-féle nodularis degeneratio corneae esetében nem az ismétlődő gyulladások okozzák a cornea degeneratioját, hanem fordítva, a degeneratio miatt kóros anyagcseréjű cornea az oka a sorozatos keratitiseknek.
APA, Harvard, Vancouver, ISO, and other styles
16

Romero, M., M. Cadena, J. Osma, and Y. Santamaria. "AB0911 PREVALENCE AND RISK FACTORS OF HIP FRACTURE ASSOCIATED WITH OSTEOPOROSIS IN A GERIATRIC POPULATION FROM COLOMBIAN NORTH EAST." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1757.1–1758. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5129.

Full text
Abstract:
Background:Hip fracture is a frequent cause of hospital admission in older adults.1The prevalence of hip fracture associated with osteoporosis in the elderly is 18% in women and 6% in men.2Likewise, the attention of this event requires an approximate value of 2,943 dollars, which represents an average of 18,95% of the per capita income of most countries.3It is also established that appropriate and timely treatment of osteoporosis can prevent the appearance of fractures.4Objectives:The aim of this study was to determine the prevalence of hip fracture associated with osteoporosis, as well as the associated factors to its presentation in a geriatric population in Colombia.Methods:Cross-sectional study that included 130 patients over 65 years old, who consulted the University Hospital of Santander with hip fracture. The main variable of exposition was the medical history of osteoporosis. Descriptive analysis was performed with absolute and relative frequency measurements for the qualitative variables and central tendency measures and dispersion according to the distribution of the variables. Subsequently, the bivariate logistic regression analysis was performed to identify the associated risk variables. The analysis was performed with the Stata 12.0 Software.Results:From the 130 patients included in the study, 33.85% corresponded to the male gender. The average age was 82.49 years with a DS of 8.35 years. The median length of hospital stay was 17.5 days with an interquartile range of 11 to 26 days. The most common comorbidity was hypertension in 65.38%, followed by diabetes and COPD in 21.54%, heart failure in 19.23% and chronic kidney disease in 17.69%. The median Charlson score was 5 with an interquartile range between 4 and 6 points. 13.85% of the patients admitted had concomitant osteoporosis, 77.7% of them were women and 8,46% of them had severe osteoporosis, with history of prior fracture, without treatment. In the bivariate analysis, an association was found between having COPD (OR: 4.89, 95% CI 1.71-13.95, p = 0.003), dementia (OR: 3.20, 95% CI 1.05-19.56, p = 0.044), malnutrition (OR: 3.42, IC95 % 1.10 - 10.60, p = 0.032), and osteoporosis associated with hip fracture at hospital admission. Likewise, a greater probability was found for the development of in-hospital pneumonia (OR: 2.48, 95% CI 1.14 - 7.98, p = 0.04) in patients with osteoporosis compared to those who did not have bone disease.Conclusion:13.85% of patients who entered due to hip fracture had osteoporosis as comorbidity, data comparable to that previously reported. Variables associated with the presence of osteoporosis at admission in patients with hip fracture were found like history of COPD, dementia, and malnutrition, which makes it likely that those patients with pathologies that decrease physical activity or food intake can impact in an important way the appearance of osteoporosis. One of the most important contributions of this study is the identification of in-hospital complication (pneumonia), which should be actively monitored in these patients.References:[1]Falaschi P (Paolo), Marsh DR. Orthogeriatrics. Springer; 2017.[2]Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: A world-wide projection. Osteoporos Int. 1992 Nov;2(6):285–9.[3]Mohd-Tahir NA, Li SC. Economic burden of osteoporosis-related hip fracture in Asia: a systematic review. Vol. 28, Osteoporosis International. Springer London; 2017. p. 2035–44.[4]Solimeo SL, Mccoy K, Reisinger HS, Adler RA, Sarrazin MV. Factors Associated With Osteoporosis Care of Men Hospitalized for Hip Fracture: A Retrospective Cohort Study. 2019;Disclosure of Interests:None declared
APA, Harvard, Vancouver, ISO, and other styles
17

Rehman, Dureshewar, Naila Perven, and Aisha Abdul Haq. "OSTEOPOROSIS." Professional Medical Journal 25, no. 09 (September 9, 2018): 1328–33. http://dx.doi.org/10.29309/tpmj/18.4835.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Dixit, Priya, Shah Waliullah, and Tabrez Jafar. "OSTEOPOROSIS: A MAJOR HEALTH PROBLEM." Era's Journal of Medical Research 7, no. 1 (June 2020): 134–41. http://dx.doi.org/10.24041/ejmr2020.22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Bairamov, Alekber A., Eugenii I. Maevsky, and Petr D. Shabanov. "Correction of bone remodeling in experimental osteoporosis." Reviews on Clinical Pharmacology and Drug Therapy 17, no. 4 (February 23, 2020): 43–50. http://dx.doi.org/10.17816/rcf17443-50.

Full text
Abstract:
The experimental work analyzes the evaluation of the pharmacological efficacy of 3 experimental samples of the anti-osteoporosic preparation, created on the basis of salts of succinic acid in comparison with the comparison drug. On the experimental model of osteoporosis, according to the application of atomic absorption spectroscopy and flame photometry of the femur, the high efficiency of the new drug in the correction of induced pathology has been proved. The data obtained indicate that when acid salts of the natural conformer of succinic acid are used, it is possible to achieve sufficient saturation of bone tissue with calcium without overloading the body with excess calcium.
APA, Harvard, Vancouver, ISO, and other styles
20

TEODORA, DOMINTEANU. "OSTEOPOROSIS, Prevent and Treat through Sport." Indian Journal of Applied Research 4, no. 4 (October 1, 2011): 222–24. http://dx.doi.org/10.15373/2249555x/apr2014/68.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Hajare, Rahul A. Hajare. "HEALTH BENEFITS OF HYDROTHERAPY IN OSTEOPOROSIS." Orthopaedics and Surgical Sports Medicine 01, no. 01 (July 30, 2018): 01. http://dx.doi.org/10.31579/2641-0427/004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Kardos, Z. "AB1403 IMPACT OF THE SARS-COV 2 PANDEMIC AND RELATED EPIDEMIOLOGICAL RESTRICTIONS ON THE CARE OF PATIENTS WITH OSTEOPOROSIS – EXPERIENCES OF A HUNGARIAN CENTRE." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1807.2–1807. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2961.

Full text
Abstract:
BackgroundTreatment of patients with osteoporosis was inadequate even before the COVID-19 pandemic. Not only patients without fracture, but only a small proportion of patients with osteoporotic fracture have treated. In Hungary only 30% of patients with osteoporosis received adequate antiporotic treatment before the pandemic. Almost 90% of whom were women, less than 10% of men. The incidence of fractures is increasing dramatically worldwide. In 2010, the vertebral fracture rate was 3.5 million in Europe but it is expected to reach 4.5 million by 2025. In 1990, osteoporosis caused 1.26 million hip fractures and by 2025 this is estimated at 2.6 million worldwide. The care for patients with osteoporosis was further aggravated by the restrictions necessarily imposed due to the coronavirus.ObjectivesThe aim of the study was to explore the extent and consequences of diagnostic and therapeutic failure in patients with osteoporosis.MethodsI determined the number of osteoporosis examinations performed in our centre in 2019-2021 from the medical database. I surveyed how many patients were discontinued the antiporotic treatment during the pandemic according to the different drug groups in Hungary and also in our centre as well as the prevalence of wrist and hip fractures due to minor trauma in our county in the pre- and post-pandemic period.ResultsIn our centre an average of 30 DEXA examinations were performed daily in the pre-pandemic period. From the end of October 2021 to the end of May 2021 there was not perform any ODM examinations. It means 3.980 missed exams and at least 1.000 missed osteoporosis diagnoses and therapy starts.More than 20% of patient were lost from the antiporotic care in Hungary. Drop-out was mainly seen in patients treated with bisphosphonates. There were 20730 bisphosphonate-treated patient in 2019, 19813 in 2020 and 17315 in 2021. Antiporotic treatment was discontinued in 30% of patients treated with bisphosphonate+vitamin-D (7849 in 2019, 6950 in 2020, 5484 in 2021) or bisphosphonate+calcium+vitamin-D fixed combination products (3256-2876-2289).In our centre, the prescribing of bisphosphonates has also decreased more than half. Patients treated with iv. bisphosphonates were interrupted or switched to oral formulations. Denosumab therapy was continuous: 581 injections were prescribed in the 12 months before and 579 during the pandemic. However, no new treatment started. In case of teriparatide, the initiated therapies were continued and even the number of prescriptions increased.As a consequence, an increase in the occurrence of fractures due to minor trauma is expected. Although epidemiological restrictions in this regard, the curfew has had some positive effects. According to international data, the number of wrist fractures has almost halved, while the data for hip fractures are controversial. The decrease of wrist fractures can also be verified in our county. The number of wrist fractures was 598 in April-May 2019, 393 in the same period in 2020, and 372 in 2021. After a significant reduction in hip fractures in 2020, there is already an upward trend in 2021 (470 in 2019, 358 in 2020, 393 in 2021). The real consequences of failure to treat osteoporosis are expected only after years.ConclusionMissed doctor-patient appointments were associated with missed diagnoses and interruptions of ongoing treatments. Fear of the virus, immobilisation due to home office and curfews, lack of exercise, sun exposure, caused depressive symptoms, increased alcohol consumption and caloric intake are all increase the risk of osteoporosis. Thus, traditional risk factors for osteoporosis expanded with the direct effects and the introduced restrictions because of the pandemic.References[1]Osteoporosis in the European Union: medical management, epidemiology and economic burden. Hernlund E. et al.Arch Osteoporos. 2013;8(1):136.[2]Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance. Hampson G et al. Calcif Tissue Int. 2021 May 18:1-12.Disclosure of InterestsNone declared
APA, Harvard, Vancouver, ISO, and other styles
23

Pacheco-Pantoja, Elda Leonor, Paloma Salazar-Ciau, and Víctor Yáñez-Pérez. "Metabolismo óseo y Osteoporosis: Conceptos y Funciones." Revista Biomédica 33, no. 1 (January 1, 2022): 22–32. http://dx.doi.org/10.32776/revbiomed.v33i1.906.

Full text
Abstract:
Nuestros huesos tienen un papel versátil en nuestro organismo: desde proporcionar estructura para el cuerpo, protección para los órganos, hasta servir como reservas de minerales, como calcio y fósforo, que son esenciales para el desarrollo y la estabilidad óseas. El esqueleto alcanza la masa ósea máxima alrededor de los 30 años, después de lo cual comienza a disminuir de manera constante. Aunque la masa ósea máxima está fuertemente determinada por la genética, muchos factores modificables pueden influir en la salud del esqueleto, como la nutrición, el ejercicio, ciertas enfermedades o medicamentos. Durante el trascurso de la vida, los huesos se remodelan, proceso donde los osteoclastos activados pueden reabsorber la superficie mineralizada y reemplazarla con hueso nuevo producido por los osteoblastos. Un deterioro de este delicado equilibrio puede resultar en los cambios fisiopatológicos apreciados en la osteoporosis. Esta revisión tuvo como objetivo abordar conceptos relacionados con el metabolismo óseo, la osteoporosis, así como los tratamientos de elección existentes, centrándose en los bisfofonatos, en particular el ibandronato.
APA, Harvard, Vancouver, ISO, and other styles
24

Tada, M., Y. Yamada, K. Mandai, and N. Hidaka. "OP0319 OSTEOSARCOPENIA INCREASES THE RISK OF FALLS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A FOUR-YEAR LONGITUDINAL STUDY." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 195. http://dx.doi.org/10.1136/annrheumdis-2021-eular.942.

Full text
Abstract:
Background:Osteosarcopenia is defined as osteoporosis combined with sarcopenia. Both osteoporosis and sarcopenia are risk factors for falls and fractures in healthy individuals1. The relationships of falls and fractures to osteosarcopenia in rheumatoid arthritis (RA) patients are unknown.Objectives:The synergistic effect of osteoporosis and sarcopenia and the impact of osteosarcopenia on falls and fractures in RA patients were investigated using four years of data from a longitudinal study.Methods:The data from a prospective, observational study (CHIKARA study: UMIN000023744) were examined. The patients were divided into four groups according to their baseline status: no sarcopenia and osteoporosis (SP-OP-); only sarcopenia (SP+OP-); only osteoporosis (SP-OP+); and both sarcopenia and osteoporosis (SP+OP+). Sarcopenia was diagnosed by the criteria of the Asia Working Group on Sarcopenia 20142. Patients with osteoporosis were defined as those having a therapeutic intervention for osteoporosis. The survival rate and Cox hazard ratio were analyzed using falls and fractures as endpoints, adjusted by age, sex, and body mass index.Results:A total of 100 RA patients (female 78%, mean age 66.1 years) were enrolled. The number of SP-OP-, SP+OP-, SP-OP+, and SP+OP+ patients was 45, 17, 27, and 11, respectively. Their baseline characteristics are shown in Table 1. A total of 35 patients had falls, and 19 patients had fractures during the four-year follow-up. The fall-free survival rate in the SP-OP-, SP+OP-, SP-OP+, and SP+OP+ groups was 75.6%, 64.7%, 51.9%, and 36.4%, respectively; that of the SP+OP+ group was significantly lower than that of the other groups (P=0.021) (Figure 1). The fracture-free survival rate in the SP-OP-, SP+OP-, SP-OP+, and SP+OP+ groups was 86.7%, 82.4%, 81.5%, and 54.5%, respectively. That of the SP+OP+ group was relatively lower than that of the other groups (P=0.121). The hazard ratio of falls was significantly increased in the SP+OP+ group by 3.32-fold (95%CI: 1.01-10.9) compared to that in the SP-OP- group, whereas that in the SP+OP- and SP-OP+ groups was 2.58-fold (95%CI: 0.75-8.8) and 2.29-fold (95%CI: 0.94-5.6) higher, respectively. There were no significant differences compared to the SP-OP- group. The hazard ratio of fractures in the SP+OP+ group was increased 2.73-fold (95%CI: 0.61-12.2) compared to that in the SP-OP- group.Table 1.Baseline characteristics of the four groupsSA-OP-SA+OP-SA-OP+SA+OP+P value*Female, %73.358.888.91000.027Age, years63 (49, 72)69 (60, 79)73 (64, 75)73 (65, 81)0.008Disease duration, years4.4 (1.0, 8.4)4.0 (1.3, 8.9)7.6 (1.5, 14.5)10.5 (3.2, 26.5)0.035DAS28-ESR3.14 (2.66, 3.70)3.55 (3.01, 4.65)3.93 (3.28, 4.63)3.53 (2.48, 3.89)0.01mHAQ0.25 (0, 0.375)0.375 (0.125, 0.875)0.375 (0.125, 0.875)0.5 (0.125, 0.875)0.065MTX, mg/week, rate (%)8.4 ± 2.9 (86.7)8.7 ± 3.5 (70.6)8.3 ± 2.8 (92.6)6.8 ± 1.0 (90.9)0.388Glucocorticoid, mg/day, rate (%)3.7 ± 1.9 (20.0)6.3 ± 1.8 (11.8)4.0 ± 1.7 (44.4)3.8 ± 1.8 (18.2)0.400Body mass index, kg/m223.4 ± 3.819.2 ± 2.321.7 ± 2.419.2 ± 2.0<0.001Data are shown as mean ± standard deviation (SD) or median (25th, 75th percentile).*: compared in four groups by Kruskal-Walls test.Figure 1.Fall-free survival rates of the four groups.Conclusion:The survival rates with the endpoints of falls and fractures in RA patients with osteosarcopenia were lower during the four-year follow-up. In particular, the risk of falls increased with the synergistic effect of osteoporosis and sarcopenia in RA patients.References:[1]Dennison, E. M. et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int30, 1733-1743, doi:10.1007/s00198-019-05002-w (2019).[2]Chen, L. K. et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc15, 95-101, doi:10.1016/j.jamda.2013.11.025 (2014).Disclosure of Interests:None declared.
APA, Harvard, Vancouver, ISO, and other styles
25

Laffaire, M., M. Caroline, E. Allado, E. Bauer, I. Chary Valckenaere, and D. Loeuille. "AB0948 Osteoporotic screening and prevalence of severe osteoporotic fractures in a population of psoriatic arthritis initiating a biologic treatment." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1602.2–1603. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3871.

Full text
Abstract:
BackgroundOsteoporosis is a common complication of Rheumatic diseases. The association between osteoporosis and rheumatoid arthritis is clearly demonstrated while this association is still debated as well as for the screening of osteoporosis by Dual-Energy X-Ray Absorptiometry (DEXA) or to demonstrate an increased risk of fracture on radiography in a population of Psoriatic Arthritis (PsA). The prevalence of fragility fractures reported on medical reports ranged between 12% and 40% in PsA patients. Only a few studies evaluated the prevalence of vertebral fracture (VF) on spine radiographs. To our knowledge no study has evaluated the contribution of radiographic or CT assessment of the spine on the prevalence of fragility fracture reported in medical records.ObjectivesTo determine Psoriatic Arthritis patient’s characteristics screened for osteoporosis by DEXA in a population initiating a biologic treatment (bDMARD) and to estimate the prevalence of severe osteoporotic fractures on medical reports and after imaging modalities scoring (X-ray or CT-scan).MethodsPatients with psoriasis should satisfy the CASPAR or ASAS criteria and have been screened during their follow up for a bDMARD. Osteoporotic screening was defined by a BMD testing (DEXA). Vertebral fractures were scored according to Genant’s method on spine X-ray or sagittal CT-scan images. Clinical and demographic data and the presence of previous severe osteoporotic fracture reported in the medical records were collected.ResultsOn 417 PsA patients screened for bDMARDs during 2008-2019, 89 patients (21.3%) were assessed for osteoporosis by DEXA. Increased age, female sex, menopause, previous severe fracture, disease duration, presence of inflammatory bowel disease, current and previous corticosteroid and bDMARDs uses were significantly associated with osteoporotic screening. On DEXA, 7 patients (7.9%) were classified as osteoporotic. The prevalence of severe osteoporotic fracture was 6.7% in medical reports and increased to 23.6% after scoring spine radiographies or TAP-CT images. In univariate analysis the presence of severe osteoporotic fractures was associated with age (p=0.013), scanographic bone attenuation coefficient (p=0.005) and Lumbar T-score (p=0.039).ConclusionLess than a quarter of PsA patients initiating a bDMARD is screened for osteoporosis. The prevalence of osteoporosis on DEXA and severe osteoporotic fractures on medical records are inferior to 10%. After systematic imaging evaluation, this prevalence increases at 23.6%.References[1]Chandran S, Aldei A, Johnson SR, Cheung AM, Salonen D, Gladman DD. Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. Seminars in Arthritis and Rheumatism. oct 2016[2]Riesco M, Manzano F, Font P, García A, Nolla JM. Osteoporosis in psoriatic arthritis: an assessment of densitometry and fragility fractures. Clinical Rheumatology. déc 2013[3]Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arthritis Res Ther. févr 2011[4]Del Puente A, Esposito A, Costa L, Benigno C, Del Puente A, Foglia F, et al. Fragility Fractures in Patients with Psoriatic Arthritis. The Journal of Rheumatology Supplement. 1 nov 2015[5]van der Weijden MAC, van der Horst-Bruinsma IE, van Denderen JC, Dijkmans BAC, Heymans MW, Lems WF. High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int. juin 2012[6]Pickhardt PJ, Pooler BD, Lauder T, del Rio AM, Bruce RJ, Binkley N. Opportunistic Screening for Osteoporosis Using Abdominal Computed Tomography Scans Obtained for Other Indications. Ann Intern Med. 16 avr 2013[7]Kwok TSH, Sutton M, Yang Ye J, Pereira D, Chandran V, Gladman DD. Prevalence and factors associated with osteoporosis and bone mineral density testing in psoriatic arthritis. Arthritis Care & Research. 16 déc 2020[8]Gulati AM et al. Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population. RMD Open. juin 2018Disclosure of InterestsNone declared
APA, Harvard, Vancouver, ISO, and other styles
26

Kahraman, E. G., S. Akar, and B. Ö. Pamuk. "AB1363-HPR EVALUATION OF SELECTION CRITERIA OF CLINICIANS IN THE TREATMENT OF OSTEOPOROSIS, OSTREQ RESEARCH IN TURKEY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1968.1–1969. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4473.

Full text
Abstract:
Background:Osteoporosis is a disease with increasing prevalence in the aging and growing world population and its insidious progression and lack of findings without fracture cause certain difficulties in the diagnosis and treatment of this disease. There are many medical and paramedical treatment options for osteoporosis, and clinicians make these treatment decisions with many factors in mind.Objectives:We wanted to evaluate the importance of these factors for clinicians through a questionnaire. This 17-question questionnaire aimed to investigate the factors that clinicians consider in the planning of osteoporosis treatment and the effect of these factors on treatment planning. We made the Turkish version of the OSTEQ questionnaire in this study which factors clinicians in planning treatment for osteoporosis in Turkey we aimed to investigate that take into consideration.Methods:OSTREQ questionnaire developed by Makraz et al. are used in this research. In this survey, which consists of 8 sections (health care system, patients’ preferences regarding regimen’s administration, usage, cost, severity of disease, treatment efficacy, safety profile and pharmaceutical industry) and 17 questions, the participants were asked to evaluate their answers with 5 different scales: Absolutely Preventive, Partially Preventive, Neither Preventive or Encouraging, Partially Encouraging, Absolutely Encouraging.Clinicians of Rheumatology, Physical Therapy and Rehabilitation, Endocrinology and Metabolic Diseases participated in our study. The questionnaires were filled in by e-mail or by inviting the participants to the our university or by going to the clinics where the clinicians were working.Results:In our study 37 (21.8%) were endocrinology, 49 (28.8%) were rheumatology and 84 (49.4%) were physical therapy and rehabilitation specialists. The overall Cronbach alpha coefficient of the questionnaire was found to be 0.855. No material was found to significantly increase the internal reliability coefficient if deleted. As a result of t-test in 27% lower and upper groups to measure the discriminative power of the items, it was seen that all items made a significant difference in the lower and upper groups, which were formed according to the total score of 27 people. Confirmatory factor analysis and internal reliability results did not require removal of the substance, so the substance was not removed. When the responses of the specialist physicians participating in our study to the osteoporosis preference criteria questionnaire were examined according to their specialty, no statistically significant difference was found between specialty branches but only significant difference was found in health system and cost subscale according to branches (p = 0.013). Post-hoc test (LSD) was used to find out the group that made a significant difference in health system and cost sub-factor. higher scores (p = 0.034).Conclusion:We developed and validated a general osteoporosis treatment questionnaire that could provide assessment of the criteria that physicians take into consideration when they decide to implement a regimen for osteoporosis. This tool could assist health care systems and pharmaceutical companies understand which parameters drive physicians’ choices regarding the treatment of osteoporosis.References:[1]P. Makras, A. Galanos, S. Rizou, A. D. Anastasilakis, and G. P. Lyritis, “Development and validation of an osteoporosis treatment questionnaire (OSTREQ) evaluating physicians’ criteria in the choice of treatment,”Hormones, vol. 15, no. 3, pp. 413–422, Jul. 2016.[2]S. Tuzunet al., “Incidence of hip fracture and prevalence of osteoporosis in Turkey: The FRACTURK study,”Osteoporos. Int., vol. 23, no. 3, pp. 949–955, Mar. 2012.Disclosure of Interests:None declared
APA, Harvard, Vancouver, ISO, and other styles
27

Lewiecki, E. Michael, Neil Binkley, and John P. Bilezikian. "Treated Osteoporosis Is Still Osteoporosis." Journal of Bone and Mineral Research 34, no. 4 (February 19, 2019): e3671. http://dx.doi.org/10.1002/jbmr.3671.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Daz Curiel, M., and M. J. Moro lvarez. "Otras formas de osteoporosis: osteoporosis masculina. Osteoporosis corticoidea. Osteoporosis asociada al trasplante de ?rganos." Medicine - Programa de Formaci?n M?dica Continuada Acreditado 9, no. 60 (June 2006): 3885–91. http://dx.doi.org/10.1016/s0211-3449(06)74347-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Pareek, Surbhi. "Calcium and Osteoporosis: An Important Mineral for Women." ESSENCE International Journal for Environmental Rehabilitation and Conservation 9, no. 1 (August 15, 2018): 178–81. http://dx.doi.org/10.31786/09756272.18.9.1.121.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Bucknall, Vittoria. "Idiopathic Juvenile Osteoporosis Presenting as Loss of Height." Central European Journal of Paediatrics 15, no. 1 (March 15, 2019): 56–62. http://dx.doi.org/10.5457/p2005-114.231.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Tsartsalis, Athanasios, Charalambos Dokos, Georgia Kaiafa, Dimitris Tsartsalis, Antonios Kattamis, Apostolos Hatzitolios, and Christos Savopoulos. "Statins, bone formation and osteoporosis: hope or hype?" HORMONES 11, no. 2 (April 15, 2012): 126–39. http://dx.doi.org/10.14310/horm.2002.1339.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Hasan, Adnan M., Taha A. Qaradaghi, and Mohammed M. Alghabsh. "PREVALENCE OF OSTEOPOROSIS AMONG THALASSEMIC CHILDREN IN SULAIMANI." Journal of Sulaimani Medical College 7, no. 3 (November 1, 2017): 249–62. http://dx.doi.org/10.17656/jsmc.10127.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

omarhamdi., Dr, ALwaleedfaydullahal idriss., Heshamzuhair ajaj., Shahadahmad bamani., and Faisalhammad alatawi. "HEALTH BELIEFS ABOUT OSTEOPOROSIS AND OSTEOPOROISIS RADIOLOGICAL SCREENING IN OLDER WOMEN AND MEN IN JEDDAH CITY 2016." International Journal of Advanced Research 5, no. 1 (January 31, 2017): 2816–29. http://dx.doi.org/10.21474/ijar01/3076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Lombardi, F. A., P. Pisani, A. Natale, E. Casciaro, M. DI Paola, R. Franchini, M. Muratore, F. Conversano, and S. Casciaro. "AB1033 RADIOFREQUENCY ECHOGRAPHIC MULTI SPECTROMETRY (REMS) FOR THE ASSESSMENT OF FEMORAL BONE HEALTH IN A MALE POPULATION." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1640.1–1640. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4566.

Full text
Abstract:
BackgroundBone mass reaches the peak during the third decade of life. By this age, men reach an increased bone mass that starts declining in their fifties, however less rapidly than women after menopause. However, men and women lose bone mass at the same rate by age 65-70, becoming fragile and more likely to have fracture.ObjectivesThis study aimed to evaluate the diagnostic accuracy in osteoporosis diagnosis of Radiofrequency Echographic Multi Spectrometry (REMS) technology applied on the proximal femur in an adult male population in comparison with the Dual-energy X-ray Absorptiometry (DXA).MethodsA cohort of Caucasian males was enrolled in the study. Inclusion criteria were: age between 30 and 90 years, body mass index (BMI) less than 40 kg/m2, no significant walking impairments and proximal femur DXA medical prescription. All the enrolled patients underwent proximal femur scans with both DXA and REMS. The agreement between REMS and DXA-measured BMD was expressed by Pearson correlation coefficient and Bland-Altman method. The classification into patients “with osteoporosis” or “without osteoporosis” was carried out considering the conventional threshold of T-score (-2.5) for both techniques independently. The accuracy was evaluated by the assessment of sensitivity and specificity considering the DXA outcome as reference [1].ResultsA total of 219 men were included in the analysis, with mean age of 55.5 (± 15.3) years. The Pearson correlation coefficient between REMS- and DXA-measured BMD values was r=0.94. At Bland-Altman analysis, Bias ± 1.96 Standard Deviation were -0.004 ± 0.04 g/cm2. The REMS capability to discriminate osteoporotic patients from non-osteoporotic ones was very high: a sensitivity of 90.0% and specificity of 91.8% was detected.ConclusionREMS, applied to the proximal femur site, is a reliable technology for the diagnosis of osteoporosis also in men, thus confirming the diagnostic performance already observed in studies carried out in female populations [1, 2].References[1]Di Paola P et al. Osteoporos Int. 2019; 30(2):391-402.[2]Adami G et al. Bone 2020; 134:115297.Disclosure of InterestsFiorella Anna Lombardi: None declared, Paola Pisani: None declared, Alessandra Natale: None declared, Ernesto Casciaro Shareholder of: Ernesto Casciaro owns stocks of Echolight Spa, Marco Di Paola: None declared, Roberto Franchini: None declared, Maurizio Muratore: None declared, Francesco Conversano Shareholder of: Francesco Conversano owns stocks of Echolight Spa, Sergio Casciaro Shareholder of: Sergio Casciaro owns stocks of Echolight Spa
APA, Harvard, Vancouver, ISO, and other styles
35

Peters, Dene C., and Stephen G. Coleman. "Osteoporosis." Drugs in R & D 1, no. 3 (January 1999): 203–9. http://dx.doi.org/10.2165/00126839-199901030-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Anderson, Paul A., Brett A. Freedman, W. Timothy Brox, and William O. Shaffer. "Osteoporosis." Journal of Bone and Joint Surgery 103, no. 8 (February 12, 2021): 741–47. http://dx.doi.org/10.2106/jbjs.20.01248.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Wells, Mary, and Inc Milner-Fenwick. "Osteoporosis." American Journal of Nursing 87, no. 1 (January 1987): 107. http://dx.doi.org/10.2307/3470412.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Bhagat, Madhura. "Osteoporosis." Acta Scientific Orthopaedics 2, no. 11 (October 14, 2019): 20–21. http://dx.doi.org/10.31080/asor.2019.02.0112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Gangar, Elizabeth. "Osteoporosis." Nursing Standard 8, no. 35 (May 25, 1994): 59–63. http://dx.doi.org/10.7748/ns.8.35.59.s62.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Kleerekoper, Michael. "Osteoporosis." Postgraduate Medicine 104, no. 4 (October 1998): 51–52. http://dx.doi.org/10.3810/pgm.1998.10.440.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Crandall, Carolyn. "Osteoporosis." Postgraduate Medicine 114, no. 3 (September 2003): 21. http://dx.doi.org/10.3810/pgm.2003.09.1487.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Katz, Warren A., Carl Sherman, and Nicholas A. DiNubile. "Osteoporosis." Physician and Sportsmedicine 26, no. 2 (February 1998): 33–42. http://dx.doi.org/10.3810/psm.1998.02.962.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Ford, M. Allison, and Martha A. Bass. "Osteoporosis." Californian Journal of Health Promotion 2, no. 3 (September 1, 2004): 5–11. http://dx.doi.org/10.32398/cjhp.v2i3.876.

Full text
Abstract:
Osteoporosis is a serious health issue causing premature disability to millions of Americans. Costs associated with this disease exceed 13.8 billion dollars per year. Women have a greater risk for osteoporosis than men. However, men are also susceptible to bone loss and osteoporosis. Osteoporosis education for the health care professional is warranted. Understanding risk factors and utilizing bone measurement techniques will result in earlier detection of osteoporosis. Adequate calcium intakes and weight bearing exercise is essential in prevention and maintenance of osteoporosis. This article discusses osteoporosis as a home health care issue.
APA, Harvard, Vancouver, ISO, and other styles
44

Freeman, Jeanne, and Lori Turner. "Osteoporosis." Californian Journal of Health Promotion 2, no. 3 (September 1, 2004): 12–29. http://dx.doi.org/10.32398/cjhp.v2i3.877.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Tóth, Edit. "Osteoporosis." Orvosi Hetilap 148, no. 9 (March 1, 2007): 425–26. http://dx.doi.org/10.1556/oh.2007.28047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Pountney, David. "Osteoporosis." Nursing Older People 19, no. 3 (April 2007): 19–21. http://dx.doi.org/10.7748/nop.19.3.19.s16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Lynda, Hawkes. "Osteoporosis." Nursing Standard 20, no. 21 (February 1, 2006): 67. http://dx.doi.org/10.7748/ns.20.21.67.s48.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Rugara, Farai. "Osteoporosis." Nursing Standard 21, no. 19 (January 17, 2007): 59. http://dx.doi.org/10.7748/ns.21.19.59.s59.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Mitra, Sajal, and Rachit Mitra. "Osteoporosis." Vidarbha Journal of Internal Medicine 32 (August 10, 2022): 115–19. http://dx.doi.org/10.25259/vjim_23_2022.

Full text
Abstract:
Bone is a dynamic tissue that is remodelled constantly throughout life. The arrangement of compact and cancellous bone provides strength and density suitable for both mobility and protection. Osteoporosis is defined as a reduction in the strength of bone that leads to an increased risk of fractures. The World Health Organisation operationally defined osteoporosis as a bone density also referred to as a T-score of <–2.5 and is associated with increased risk of fractures. Bone remodelling is regulated by multiple hormones, including oestrogens (in both genders), androgens, Vitamin D and parathyroid hormone (PTH), as well as locally produced growth factors, such as IGF-I, transforming growth factor β, PTH-related peptide (PTHrP), interleukins, prostaglandins and members of the tumour necrosis factor superfamily. The risk of fracture can be predicted by the Fracture Risk Assessment score. Several non-invasive techniques are available for estimating skeletal mass or bone mineral density including single energy X-ray absorptiometry, dual-energy X-ray absorptiometry, quantitative computed tomography and ultra-sound. Total daily calcium intakes <400 mg are detrimental to the skeleton. The recommended daily required intake of 1000–1200 mg for adults accommodates population heterogeneity in controlling calcium balance. For optimal skeletal health, serum 25(OH)D should be >75 nmol/L (30 ng/mL). Bisphosphonates have become the mainstay of osteoporosis treatment. Calcitonin preparations are approved by the FDA for osteoporosis in women >5 years past menopause. Denosumab was approved by the FDA in 2010. Parathormone analogues augment trabecular bone mineral density and reduce fracture occurrence. PTH (1–34) (teriparatide) produced substantial increments in bone mass. Abaloparatide is a synthetic analogue of human PTHrP, which has significant homology to PTH and also binds the PTH Type 1 receptor increasing the bone mass. Ageing is associated with progressive decline in overall muscle strength and bone loss. Resistance training increases bone strength and density, reducing the risk of fracture during a fall. Increased levels of endurance, strength and balance with exercises increase the threshold for disability and dependence as we age. Inactive and sedentary lifestyle should be discouraged. Treatment accessibility could be improved and treatment adherence should be encouraged.
APA, Harvard, Vancouver, ISO, and other styles
50

Lewiecki, E. Michael. "Osteoporosis." Annals of Internal Medicine 155, no. 1 (July 5, 2011): ITC1. http://dx.doi.org/10.7326/0003-4819-155-1-201107050-01001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Osteoporsis' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography